体外诊断行业周报3.2-3.6：政策驱动与前沿技术融合，IVD行业迎十五五发展新机遇-20260308

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [5][56]. Core Insights - The IVD industry is expected to benefit from policy support and market access optimization as part of the "14th Five-Year Plan," which emphasizes high-end medical devices and innovative technologies [4][5]. - The domestic IVD industry is in a bottoming phase, with significant progress in the localization of biochemical diagnostics, reducing reliance on foreign technologies [5][56]. - The report highlights growth opportunities in the IVD sector driven by technological integration, domestic substitution, and new screening scenarios [4][5]. Summary by Sections Industry Performance - The pharmaceutical and biological sector fell by 2.78%, while the IVD sector rose by 0.18% during the week [1]. - The IVD sector's current PE (ttm) is 39.41X, with a PB (lf) of 1.80X, showing slight increases from the previous week [3]. Market Trends - The "14th Five-Year Plan" outlines 109 major projects across six areas, focusing on public health, medical services, and innovative technologies, which will directly benefit the IVD sector [4]. - The report suggests that advancements in biomedicine materials could alleviate supply chain constraints for IVD reagents [4]. Investment Recommendations - The report recommends focusing on the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics, highlighting companies like YHLO and Shengxiang [6][56].